natgillin/translations-raw huggingface dataset:
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE 
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEPORABLJENEGA
Benazepril hydrochloride is a prodrug hydrolysed in vivo to its active metabolite, benazeprilat. 
Benazepril hidroklorid je predzdravilo, hidrolizirano in vivo v aktivni metabolit, benazeprilat.
Scientific conclusions and grounds for amendment of the summaries of product characteristics, labelling and package leaflets 
Znanstveni zaključki in razlogi za spremembo povzetka glavnih značilnosti zdravila, označevanja in navodil za uporabo
The systemic bioavailability is incomplete (~13% in dogs) due to incomplete absorption (38% in dogs) and first pass metabolism. 
Sistemska biološka uporabnost je nepopolna (~ 13 % pri psih) zaradi nepopolne absorpcije (38 % pri psih) in presnove prvega prehoda.
The product is authorised for the treatment of heart failure in dogs and in some Member States for treatment of chronic kidney disease in cats and dogs. 
Zdravilo je odobreno za zdravljenje srčnega popuščanja pri psih, v nekaterih državah članicah pa tudi za zdravljenje kronične bolezni ledvic pri mačkah in psih.
In the absence of sufficient data in cats (and dogs), it cannot be ruled out that benazepril treatment during pregnancy could be potentially harmful. 
Ker podatkov za mačke (in pse) ni, ni mogoče izključiti morebitne škodljivosti zdravljenja z zdravilom benazepril med brejostjo.
The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon. 
Odmerek se lahko podvoji, še vedno se ga daje enkrat dnevno, do najmanjšega odmerka 0,5 mg/kg (razpon 0,5 - 1,0), če veterinar presodi in svetuje, da je to klinično potrebno.
Tablets for dogs 
Tablete za pse.
No effect of “Product name” (to be completed nationally) on survival in cats with CKD has been shown, but “Product name” (to be completed nationally) increased the appetite of the cats, particularly in more advanced cases. 
Dokazanega ni bilo nobenega učinka „ime izdelka” (dopolniti na nacionalni ravni) na preživetje pri mačkah s KLB, vendar pa je „ime izdelka” (dopolniti na nacionalni ravni) povečal apetit mačk, še posebej v bolj napredujočih primerih.
Benazeprilat is excreted 54% via the biliary and 46% via the urinary route in dogs and 85% via the biliary and 15% via the urinary route in cats. 
Benazeprilat se v 54 % izloča prek žolčne in v 46 % prek sečne poti pri psih ter v 85 % prek žolčne in v 15 % prek sečne poti pri mačkah.
Data from clinical trials in conjunction with bibliographic information and experience of clinical experts is regarded to sufficiently support that benazepril treatment is beneficial for cats with CKD and proteinuria. 
Podatki iz kliničnih preskušanj v povezavi z bibliografskimi podatki in izkušnje kliničnih strokovnjakov v zadostni meri podpirajo koristnost zdravljenja z benazeprilom za mačke s kronično boleznijo ledvic in proteinurijo.
Pregnant women should take special care to avoid accidental oral exposure because ACE inhibitors have been found to affect the unborn child during pregnancy in humans. 
Noseče ženske morajo biti posebno pozorne, da preprečijo nenameren stik z usti, saj je bilo ugotovljeno, da zaviralci ACE vplivajo na nerojenega otroka med nosečnostjo pri ljudeh.
Use during pregnancy, lactation 
Uporaba v obdobju brejosti, laktacije
Benazeprilat concentrations decline biphasically: the initial fast phase (t1/2=1.7 hours in dogs and t1/2=2.4 hours in cats) represents elimination of free drug, while the terminal phase (t1/2=19 hours in dogs and t1/2=29 hours in cats) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues. 
Koncentracije benazeprilata upadajo dvofazno: začetna hitra faza (t1/2 = 1,7 ure pri psih in t1/2 = 2,4 ure pri mačkah) predstavlja sproščanje prostega zdravila, medtem ko zaključna faza (t1/2 = 19 ur pri psih in t1/2 = 29 ur pri mačkah) odraža sproščanje benazeprilata, ki je bil vezan na ACE, predvsem v tkivih.
<Marketing authorisation holder <and manufacturer>>: To be completed nationally 
<Imetnik dovoljenja za promet z zdravilom <in izdelovalec>>: dopolniti na nacionalni ravni
MARKETING AUTHORISATION NUMBER(S) To be completed nationally. 
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET Dopolniti na nacionalni ravni.
Dogs: Treatment of heart failure at stages 2,3 and 4. 
Psi: Zdravljenje srčnega popuščanja pri stopnji 2, 3 in 4.
In dogs and cats with chronic kidney disease there may be a moderate increase in levels of creatinine, an indicator of kidney function, in the blood. 
Pri psih in mačkah s kronično ledvično boleznijo lahko pride do zmernega povišanja vrednosti kreatinina, indikatorja delovanja ledvic, v krvi.
Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans. 
Noseče ženske morajo biti posebno pozorne, da preprečijo nenameren stik z usti, saj je bilo ugotovljeno, da zaviralci angiotenzinske konvertaze (ACE) vplivajo na nerojenega otroka med nosečnostjo pri ljudeh.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES Benazepril hydrochloride 
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGIH SNOVI Benazepril hidroklorid
INDICATIONS “Product name” (to be completed nationally) belongs to a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors. 
INDIKACIJA(E) „Ime izdelka” (dopolniti na nacionalni ravni) spada v skupino zdravil, imenovanih zaviralci angiotenzinske konvertaze (ACE).
For reduction of proteinuria associated with chronic kidney disease in cats. 
Za zmanjševanje proteinurije, povezane s kronično ledvično boleznijo pri mačkah.
In dogs with chronic kidney disease there may be a moderate increase in levels of creatinine, an indicator of kidney function, in the blood. 
Pri psih s kronično ledvično boleznijo lahko pride do zmernega povišanja vrednosti kreatinina, indikatorja delovanja ledvic, v krvi.
The efficacy and safety of “product name” (to be completed nationally) has not been established in dogs below 2.5 kg body weight. 
Učinkovitost in varnost „ime izdelka” (dopolniti na nacionalni ravni) nista bili ugotovljeni pri psih s telesno maso pod 2,5 kg.
2100 Köpenhamn Danmark 
2100 Köpenhamn Danska
Your veterinary surgeon may recommend to monitor plasma potassium concentrations when using “product name” (to be completed nationally) in combination with a potassium-sparing diuretic because of the risk of hyperkalaemia (high blood potassium). 
Vaš veterinar lahko priporoči spremljanje plazemskih koncentracij kalija pri uporabi „ime izdelka” (dopolniti na nacionalni ravni) v kombinaciji z diuretikom, ki zadržuje kalij, zaradi tveganja hiperkalemije (visok krvni kalij).
In cats and dogs with chronic kidney disease, “product name” (to be completed nationally) may increase plasma creatinine concentrations at the start of therapy. 
Pri mačkah in psih s kronično ledvično boleznijo lahko „ime izdelka” (dopolniti na nacionalni ravni) poveča plazemske koncentracije kreatinina na začetku zdravljenja.
However, a precaution regarding use in dogs with instable kidney disease should be added to the product information since Fortekor treatment of dogs with heart failure and concomitant instable kidney disease could further deteriorate renal function. 
Vendar je treba k informacijam o zdravilu Fortekor dodati previdnostno opozorilo za uporabo pri psih z nestabilno boleznijo ledvic, saj lahko zdravljenje z zdravilom Fortekor pri psih s srčnim popuščanjem in sočasno nestabilno boleznijo ledvic dodatno poslabša delovanje ledvic.
Weight of dog (kg) 
Masa psa (kg)
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Carboard box 
PODATKI NA ZUNANJI OVOJNINI Kartonasta škatla
Benazepril reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg body weight for 52 weeks. 
Benazepril zmanjša maso jajčnikov/jajcevodev pri mačkah, če ga 52 tednov dajemo dnevno po 10 mg/kg.
Given that no risks has been identified during treatment of cats that would restrict the use and furthermore, that sufficient support for efficacy is available, the benefit-risk balance is regarded positive for Fortekor for the following indication in cats: “Reduction of proteinuria associated with chronic kidney disease”. 
Ker pri zdravljenju mačk niso opredelili tveganj, ki bi omejila uporabo, in ker je na voljo dovolj podpornih podatkov za učinkovitost, je ocena razmerja med tveganji in koristmi za zdravilo Fortekor pozitivna za naslednje indikacije pri mačkah: »Zmanjšanje proteinurije, povezane s kronično boleznijo ledvic«.
2100 København Ø Danmark 
2100 København Ø Danska
2100 Kööpenhamina Tanska 
2100 Kööpenhamina Danska
Pharmacotherapeutic group: ACE Inhibitors, plain. 
Farmakoterapevtska skupina: Zaviralci ACE, navadni.
In contrast with other ACE inhibitors, benazeprilat is excreted equally by both biliary and urinary routes in dogs and 85% via the biliary and 15% via the urinary route in cats, and therefore no adjustment of the dose of “product name” (to be completed nationally) is necessary in the treatment of cases with renal insufficiency. 
Za razliko od drugih zaviralcev ACE se benazeprilat izloča enakovredno tako prek žolčne kot prek sečne poti pri psih ter v 85 % prek žolčne in v 15 % prek sečne poti pri mačkah, zaradi česar odmerka „ime izdelka” (dopolniti na nacionalni ravni) v primeru ledvične insuficience ni treba prilagajati.
Benazeprilat concentrations decline biphasically: the initial fast phase (t1/2=1.7 hours in dogs) represents elimination of free drug, while the terminal phase (t1/2=19 hours in dogs) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues. 
Koncentracije benazeprilata upadajo dvofazno: začetna hitra faza (t1/2 = 1,7 ure pri psih) predstavlja sproščanje prostega zdravila, medtem ko zaključna faza (t1/2 = 19 ur pri psih) odraža sproščanje benazeprilata, ki je bil vezan na ACE, predvsem v tkivih.
In dogs with chronic kidney disease, “product name” (to be completed nationally) may increase plasma creatinine concentrations at the start of therapy. 
Pri psih s kronično ledvično boleznijo lahko „ime izdelka” (dopolniti na nacionalni ravni) poveča plazemske koncentracije kreatinina na začetku zdravljenja.
Given that in principle no risks has been identified during treatment of dogs that would restrict the use and furthermore, that sufficient support for efficacy is available the benefit-risk balance is regarded positive for Fortekor for the following indication in dogs: “Treatment of congestive heart failure in dogs”. 
Ker načeloma pri zdravljenju psov niso opredelili tveganj, ki bi omejila uporabo, in ker je na voljo dovolj podpornih podatkov za učinkovitost, je ocena razmerja med tveganji in koristmi za zdravilo Fortekor pozitivna za naslednje indikacije pri psih: »Zdravljenje kongestivnega srčnega popuščanja pri psih«.
Due to this a precaution for treatment of dogs with heart failure and concomitant uncontrolled kidney disease should be added to the product information. 
Zaradi tega je treba pri zdravljenju psov s srčnim popuščanjem in sočasno boleznijo ledvic, ki ni pod nadzorom, k informacijam o zdravilu dodatno previdnostno opozorilo.
However, benazepril treatment of dogs with unstable kidney disease involves an increased risk for deterioration of renal function due to the reduction of peripheral blood pressure leading to a decline in glomerular filtration rate and worsening azotemia. 
Zdravljenje psov z nestabilno boleznijo ledvic pa je povezano z večjim tveganjem za poslabšanje ledvičnega delovanja zaradi znižanja perifernega krvnega tlaka, kar povzroči zmanjšanje hitrosti
Reduction of proteinuria associated with chronic kidney disease. 
Zmanjševanje proteinurije, povezane s kronično ledvično boleznijo.
In double-blind clinical trials in dogs with congestive heart failure, “product name” (to be completed nationally) was well tolerated with an incidence of adverse reactions lower than observed in placebotreated dogs. 
V dvojno slepih kliničnih preizkusih so psi s kongestivnim srčnim popuščanjem „ime izdelka” (dopolniti na nacionalni ravni) dobro prenašali, pojavnost neželenih reakcij pa je bila nižja od tiste pri s placebom zdravljenih psih.
Treatment of heart failure at 2nd3rd and 4th stage. 
Zdravljenje srčnega popuščanja pri 2., 3. in 4. stopnji.
Do not use in case of hypersensitivity to the active substance or to any of the excipients. 
Ne uporabljajte v primeru preobčutljivosti na zdravilno učinkovino ali katerokoli izmed pomožnih snovi.
Dogs: For the symptomatic, adjunctive therapy in the treatment with the diuretic furosemide of heart failure caused by mitral failure or congestive cardiomyopathy. 
Psi: Za simptomatsko, dodatno zdravljenje pri zdravljenju srčnega popuščanja (zaradi popuščanja mitralne zaklopke ali kongestivne kardiomiopatije) z diuretikom furosemidom.
The efficacy and safety of “product name” (to be completed nationally) has not been established in dogs and cats below 2.5 kg body weight. 
Učinkovitost in varnost „ime izdelka” (dopolniti na nacionalni ravni) nista bili ugotovljeni pri psih in mačkah s telesno maso pod 2,5 kg.
No considerable deviations in pharmacokinetics of benazepril were noted after long-term treatment or in cats with renal insufficiency, and no adjustment of dose is therefore necessary. 
Po dolgotrajnem zdravljenju ali pri mačkah z ledvično insuficienco niso opazili večjih odstopanj v farmakokinetiki benazeprila, zato odmerka ni treba prilagoditi.
Treatment of congestive heart failure. 
Zdravljenje kongestivnega srčnega popuščanja.
In dogs with congestive heart failure, “product name” (to be completed nationally) has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products without demonstrable adverse interactions. 
Pri psih s kongestivnim srčnim popuščanjem so „ime izdelka” (dopolniti na nacionalni ravni) dajali v kombinaciji z digoksinom, diuretiki, pimobendanom in antiaritmičnimi zdravili za uporabo v veterinarski medicini brez dokazljivega neželenega medsebojnega delovanja.
No data have been presented that clearly demonstrate benefit of benazepril treatment of cats with CKD on survival. 
Podatki, ki bi jasno dokazovali koristi zdravljenja mačk s kronično boleznijo ledvic z benazeprilom za preživetje, niso bili predloženi.
For cats over 2.5 kg Treatment of chronic renal insufficiency 
Za mačke nad 2,5 kg Zdravljenje kronične ledvične insuficience
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION To be completed nationally. 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Dopolniti na nacionalni ravni.
In dogs, peak benazeprilat concentrations (Cmax of 37.6 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 1.25 hours. 
Pri psih so največje koncentracije benazeprilata (Cmax 37,6 ng/ml po odmerku 0,5 mg/kg benazepril hidroklorida) dosegli v Tmax 1,25 ure.
Treatment of renal insufficiency 
Zdravljenje ledvične insuficience
One clinical field trial was submitted to support effect of benazepril treatment of dogs with CKD. 
Predloženo je bilo eno klinično preskušanje na terenu, ki je podprlo učinke zdravljenja z benazeprilom pri psih s kronično boleznijo ledvic.
In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. 
Pri ljudeh lahko kombinacija zaviralcev ACE in nesteroidnih protivnetnih zdravil (NSAID) vodi do zmanjšane antihipertenzivne učinkovitosti ali do okvare delovanja ledvic.
In dogs with congestive heart failure, “product name” (to be completed nationally) has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic products without evidence of associated adverse reactions. 
Pri psih s kongestivnim srčnim popuščanjem so „ime izdelka” (dopolniti na nacionalni ravni) dajali v kombinaciji z digoksinom, diuretiki, pimobendanom in antiaritmičnimi zdravili brez dokazljivega neželenega medsebojnega delovanja.
Dog: Treatment of heart failure Cat: Retardation of chronic renal insufficiency by reducing the blood pressure. 
Mačka: Zavlačevanje kronične ledvične insuficience z zniževanjem krvnega pritiska.
In cats, peak benazeprilat concentrations (Cmax of 77.0 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 2 hours. 
Pri mačkah so največje koncentracije benazeprilata (Cmax 77,0 ng/ml po odmerku 0,5 mg/kg benazepril hidroklorida) dosegli v Tmax 2 uri.
After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly (Tmax 0.5 hour in dogs and within 2 hours in cats) and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat. 
Po peroralni uporabi benazepril hidroklorida so najvišje ravni benazeprila hitro dosežene (tmax 0,5 ure pri psih in v roku 2 ur pri mačkah) in hitro upadejo, ker jetrni encimi zdravilo delno presnovijo v benazeprilat.
In humans, the combination of ACE inhibitors and NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) can lead to reduced anti-hypertensive efficacy or impaired kidney function. 
Pri ljudeh lahko kombinacija zaviralcev ACE in NSAID (nesteroidnih protivnetnih zdravil) vodi do zmanjšane antihipertenzivne učinkovitosti ali do okvare delovanja ledvic.
Strengths Pharmaceutical forms 
Farmacevtske oblike
20 mg Tablets 
20 mg Tablete
It is prescribed by the veterinary surgeon for the treatment of congestive heart failure in dogs and for reduction of proteinuria associated with chronic kidney disease in cats. 
Predpiše ga veterinar za zdravljenje kongestivnega srčnega popuščanja pri psih ter za zmanjševanje protinurije, povezane s kronično ledvično boleznijo, pri mačkah.
Treatment of heart failure Cats: 
Zdravljenje srčnega popuščanja Mačke:
“Product name” (to be completed nationally) reduced erythrocyte counts in normal cats when dosed at 10 mg/kg body weight once daily for 12 months and in normal dogs when dosed at 150 mg/kg body weight once daily for 12 months, but this effect was not observed at the recommended dose during clinical trials in cats or dogs. 
„Ime izdelka” (dopolniti na nacionalni ravni) je zmanjšal število eritrocitov pri zdravih mačkah v odmerku 10 mg/kg enkrat dnevno 12 mesecev in pri zdravih psih v odmerku 150 mg/kg enkrat dnevno 12 mesecev, vendar tega učinka ni bilo opaziti pri priporočenem odmerku v kliničnih preizkusih pri mačkah in psih.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER To be completed nationally. 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Dopolniti na nacionalni ravni.
Treatment of heart failure, especially dilated cardiomyopathy and mitral failure. 
Zdravljenje srčnega popuščanja, še posebej dilatativne kardiomiopatije in popuščanja mitralne zaklopke.
“Product name” (to be completed nationally) causes long-lasting inhibition of plasma ACE activity in dogs and cats, with more than 95% inhibition at peak effect and significant activity (>80% in dogs and >90% in cats) persisting 24 hours after dosing. 
„Ime izdelka” (dopolniti na nacionalni ravni) povzroči dolgotrajno zaviranje plazemske aktivnosti ACE pri psih in mačkah z več kot 95-odstotno inhibicijo pri največjem učinku in opazno aktivnost (> 80 % pri psih in > 90 % pri mačkah), ki deluje 24 ur po odmerjanju.
Repeated administration of “product name” (to be completed nationally) leads to slight bioaccumulation of benazeprilat (R=1.47 in dogs and R=1.36 in cats with 0.5 mg/kg), steady state being achieved within a few days (4 days in dogs). 
Večkratna uporaba „ime izdelka” (dopolniti na nacionalni ravni) vodi v rahlo bioakumulacijo benazeprilata (R = 1,47 pri psih in R = 1,36 pri mačkah z 0,5 mg/kg), pri čemer je dinamično ravnovesje doseženo v nekaj dneh (4 dni pri psih).
Grounds for amendment of the summaries of product characteristics, labelling and package leaflets 
Razlogi za spremembo povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo
In cats with experimental renal insufficiency,“product name” (to be completed nationally) normalized the elevated glomerular capillary pressure and reduced the systemic blood pressure. 
Pri mačkah z eksperimentalno ledvično odpovedjo je „ime izdelka” (dopolniti na nacionalni ravni) normaliziral povišani glomerularni kapilarni pritisk in zmanjšal sistemski krvni pritisk.
After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly (Tmax 0.5 hour in dogs) and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat. 
Po peroralni uporabi benazepril hidroklorida so najvišje ravni benazeprila hitro dosežene (tmax 0,5 ure pri psih) in hitro upadejo, ker jetrni encimi zdravilo delno presnovijo v benazeprilat.
In dogs with congestive heart failure, the dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg (range 0.5-1.0) benazepril hydrochloride/kg body weight if judged necessary and advised by the veterinary surgeon. 
Pri psih s kongestivnim srčnim popuščanjem se lahko odmerek podvoji, še vedno se ga daje enkrat dnevno, do najmanjšega odmerka 0,5 mg (razpon 0,5 - 1,0) benazepril hidroklorida/kg telesne mase, če veterinar presodi, da je to potrebno.
Tablets for cats and dogs 
Tablete za mačke in pse.
“Product name” (to be completed nationally) reduced erythrocyte counts in normal dogs when dosed at 150 mg/kg body weight once daily for 12 months, but this effect was not observed at the recommended dose during clinical trials in dogs. 
„Ime izdelka” (dopolniti na nacionalni ravni) je zmanjšal število eritrocitov pri zdravih psih v odmerku 150 mg/kg enkrat dnevno 12 mesecev, vendar tega učinka ni bilo opaziti pri priporočenem odmerku v kliničnih preizkusih pri psih.
Dog: Treatment of heart failure, especially dilated cardiomyopathy and mitral failure. 
Pes: Zdravljenje srčnega popuščanja, še posebej dilatativne kardiomiopatije in popuščanja mitralne zaklopke.
Therefore, the use of Fortekor during pregnancy and lactation should be contraindicated in cats (and dogs) appropriate text should be added to the relevant sections of the product information. 
Poleg tega je zdravljenje z zaviralci ACE kontraindicirano med brejostjo in laktacijo, zato mora biti uporaba zdravila Fortekor med brejostjo in laktacijo pri mačkah (in psih) kontraindicirana, v ustrezna poglavja informacij o zdravilu pa se doda ustrezno besedilo.
2,5 mg Tablets 
2,5 mg Tablete
Transient reversible hypotension (low blood pressure) may occur in cases of accidental overdose. 
V primeru nenamernega prevelikega odmerjanja se lahko pojavi prehodna reverzibilna hipotenzija (nizek krvni pritisk).
Summaries of product characteristics, labelling and package leaflets 
Povzetki glavnih značilnosti zdravil, označevanja in navodila za uporabo
Cardiac failure in dogs, chronic renal insufficiency in cats 
Srčno popuščanje pri psih, kronična ledvična insuficienca pri mačkah
“Product name”2.5 mg (to be completed nationally) 1 tablet 2 tablets 
„Ime izdelka” 2,5 mg (dopolniti na nacionalni ravni) 1 tableta 2 tableti
Repeated administration of “product name” (to be completed nationally) leads to slight bioaccumulation of benazeprilat (R=1.47 in dogs with 0.5 mg/kg), steady state being achieved within a few days (4 days in dogs). 
Večkratna uporaba „ime izdelka” (dopolniti na nacionalni ravni) vodi v rahlo bioakumulacijo benazeprilata (R = 1,47 pri psih z 0,5 mg/kg), pri čemer je dinamično ravnovesje doseženo v nekaj dneh (4 dni pri psih).
For cats -Treatment of chronic renal insufficiency 
Za mačke - Zdravljenje kronične ledvične insuficience
“Product name” 5 mg (to be completed nationally ) 0.5 tablet 1 tablet 
„Ime izdelka” 5 mg (dopolniti na nacionalni ravni) 0,5 tablete 1 tableta
2.5 mg Tablets 
2.5 mg Tablete
MARKETING AUTHORISATION HOLDER To be completed nationally. 
IMETNIK DOVOLJENJA ZA PROMET Dopolniti na nacionalni ravni.
Cats: Treatment of chronic renal insufficiency. 
Mačke: Zdravljenje kronične ledvične insuficience.